Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
Related Posts
Thorp M, Balakasi K, van Oosterhout JJ, Ramesh M, Robson I, Choko A, Shoptaw S, Hoffman R, Cornell M, Dovel K. High-Risk Mobility and Interruption[...]
Heerspink HJL, Neuen BL, Agarwal R, Cherney DZI, Lam CSP, Tuttle KR, Wanner C, Sarafidis P, Chertow GM, Friede T, Barratt J, Floege J, Chew-Wong[...]
Song J, Daniel M, Ardehali A. Not Yet a Nail in the Coffin for Ex Vivo Heart Perfusion. Ann Thorac Surg. 2026 Nov 15:S0003-4975(26)01175-6. doi:[...]